Stereotaxis Receives Buy Rating from TD Cowen with $5 Price Target

TD Cowen analyst Josh Jennings reiterated a Buy rating on Stereotaxis with a price target of $5.00. The analyst covers the Healthcare sector and has a 2.6% average return and a 50.50% success rate on recommended stocks. The current analyst consensus on Stereotaxis is a Strong Buy with an average price target of $4.67.

TD Cowen analyst Josh Jennings has reiterated his Buy rating on Stereotaxis Inc. (STXS), with a new price target of $5.00. Jennings, who covers the Healthcare sector, has an average return of 2.6% and a success rate of 50.50% on recommended stocks. His latest assessment comes amidst a strong consensus among analysts, with an average price target of $4.67, indicating a Strong Buy rating [2].

Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, has seen its stock price experience high volatility recently. On Thursday, July 17, 2025, the stock closed at $2.38, following a 0.418% decline from the previous day's close of $2.39. The stock has shown resilience, rising in 7 of the last 10 days and increasing by 10.19% over the past two weeks [1]. Jennings' optimism is rooted in the company's robust technological advancements and strong clinical trial results, which have demonstrated significant improvements in treating heart arrhythmias.

The company's recent financial performance has also been notable. In the first quarter of 2025, Stereotaxis reported total revenue of $7.5 million, a 9% year-over-year increase. Recurring revenue grew by 29% to $5.5 million, while system revenue decreased to $2.0 million. Despite a net loss of $5.8 million, the company ended the quarter with $10.7 million in cash and no debt [2].

Stereotaxis' recent announcements, including the $12.5 million registered direct offering of common stock and the publication of first clinical results for its MAGiC catheter, have further bolstered investor confidence. The company's focus on product commercialization, research and development, and strategic partnerships underscores its commitment to innovation and growth in the medical robotics sector [2].

In light of these developments, Jennings' Buy rating and price target of $5.00 reflect a bullish outlook on Stereotaxis' future prospects. As the company continues to make strides in its technological advancements and expands its market reach, investors should closely monitor its progress and consider the analyst's recommendations.

References:

[1] https://stockinvest.us/stock/STXS
[2] https://www.stocktitan.net/news/STXS/